



Diversity, Antimicrobial Susceptibility patterns, and Biofilm Formation of *Staphylococcus* spp. in Cosmetic Products in Western Saudi Arabia



Fawziah M. Albarakaty^{1,2}, Manahel S. Alharby^{1,2}, Reem A. Alghamdi^{1,2}, Leena A. Neyaz^{1,2} , Shmoukh A. Alghuraibi³ and Hussein H. Abulreesh^{1,2,*} 

¹Department of Biology, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia

²Research Laboratories Unit, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia

³Al Borg Diagnostics, Research and Development Unit, Al Borg Medical Laboratories, Jeddah, Saudi Arabia

Abstract:

Background: Cosmetics have become essential for skincare, makeup, and hair care. Cosmetic products can be contaminated during production and application. This study investigated the staphylococci contamination parameters (virulence factors, diversity, and antimicrobial susceptibility patterns) in cosmetic products in Western Saudi Arabia.

Materials and Methods: A total of 250 cosmetic products were purchased from local outlets. Staphylococci prevalence was tested through standard microbiological culturing methods, whereas the Vitek-2 compact system confirmed the presence of different staphylococci genera and revealed its antimicrobial susceptibility patterns. Moreover, PCR protocols were performed to detect virulence factors encoding genes.

Results: The data revealed a low prevalence of *Staphylococcus* spp. in cosmetics (10.4%, n = 26). Lipstick, face powder, and blusher samples comparatively presented higher contamination rates. *Staphylococcus xylosum*, *S. epidermidis*, and *S. aureus* were among the identified species. The results of antimicrobial susceptibility patterns demonstrated benzylpenicillin resistance in most of the isolates (61.53%), whereas oxacillin and erythromycin resistance was noted in 26.9% of isolates. Contrarily, the isolates were not resistant to tigecycline, gentamicin, nitrofurantoin, or linezolid. Approximately 19.2% of the isolates exhibited resistance to multiple antimicrobial classes, indicating the presence of multidrug-resistant (MDR) strains. Methicillin-resistant *Staphylococcus aureus* (MRSA) was isolated from lipstick and concealer. Biofilm formation-encoding genes (*icaA* and *icaB*) were detected in 50% (4) of the potentially pathogenic isolates, whereas *icaR*, *icaC*, and *icaD* genes were noted in 37.5% (3) of the isolates. The *mecA* resistance gene was detected in 37.5% (3, n = 8) of *Staphylococcus* spp. isolates.

Conclusion: Poor quality cosmetic products may act as a medium for the transmission of potentially pathogenic, antibiotic-resistant *Staphylococcus* spp. The results necessitate proper storage and handling of cosmetic products to avoid microbial contaminations.

Keywords: *Staphylococcus* spp., Cosmetics, Antimicrobial resistance, Biofilm, Cosmetic products, Contamination.

© 2025 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Biology, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia; Phone: +966555519597, Research Laboratories Unit, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia; E-mail: hhabulreesh@uqu.edu.sa

Cite as: Albarakaty F, Alharby M, Alghamdi R, Neyaz L, Alghuraibi S, Abulreesh H. Diversity, Antimicrobial Susceptibility patterns, and Biofilm Formation of *Staphylococcus* spp. in Cosmetic Products in Western Saudi Arabia. Open Microbiol J, 2025; 19: e18742858384075. <http://dx.doi.org/10.2174/0118742858384075250402230933>



CrossMark

Received: January 10, 2025

Revised: February 23, 2025

Accepted: March 19, 2025

Published: April 15, 2025



Send Orders for Reprints to
reprints@benthamscience.net

1. INTRODUCTION

Millions of global consumers daily apply cosmetics to improve their appearance. Cosmetic products do not require a prescription like medicines. Therefore, cosmetics-related regulations are comparatively less strict than prescription drugs [1, 2]. The cosmetic products' formulations with a higher ratio of water and surfactants are more susceptible to microbial contamination. Minerals, plants, animal-based raw materials, and water content facilitate bacterial contamination in cosmetic products. Additionally, improper and lack of hygiene manufacturing practices could aid microbial contamination of cosmetics [3]. The opportunistic/ pathogenic bacterial contamination in cosmetic products can transmit infections among consumers. The production environment and organic ingredients (lipids, sugar, organic acids, and proteins) also favor microbial contamination in unused cosmetic products [4]. The rising interest in skin microbiota has raised the attention of the cosmetic industry to maintain good health of the cutaneous barrier [5]. Microorganisms are crucial for maintaining the immune system and skin barrier, and restricting pathogenic growth [6]. Skin microbiota imbalance (dysbiosis) can cause various skin illnesses, such as dry and sensitive skin, atopic dermatitis, and acne [5]. Improper cosmetics handling can result in transmittable eye and skin infections [7, 8]. Skin products (cream and powder), eye products (eyeliner and mascara), and hairdressing procedures pose skin infection risks [9, 10].

Fungal pathogens such as *Penicillium* spp., and opportunistic yeasts such as *Candida* spp. and *Rhodotorula* spp., as well as bacterial pathogens including *Pseudomonas aeruginosa* and *S. aureus*, have been reported in beauty products [7-11]. *Staphylococcus aureus* is particularly significant regarding abscesses and skin infections such as scalded skin syndrome in humans [12, 13]. *S. epidermidis* is also known to cause skin infections, bullous impetigo, hair follicle infections, and boils, particularly in beauty and hairdressing salons. Therefore, hygienic handling can restrict bacterial contamination and

transmission among users of cosmetic products. *S. epidermidis* and *S. aureus* are sources of multiple hospital- and community-acquired human illnesses that have been reported in various studies [10, 11, 14].

Staphylococcus spp.-associated infections may not all be reported, however, the number of reported cases of *S. aureus* infections is increasing dramatically around the world [12]. It was estimated that more than 80000 cases of methicillin-resistant *Staphylococcus aureus* (MRSA)-associated infections reported in the United States alone in 2011, resulting in more than 10000 deaths [12], this figure may have been sharply increased in the past 10 years. The increased number of infections due to *Staphylococcus* spp., particularly *S. aureus* may be linked with multidrug-resistance patterns observed in *Staphylococcus* spp. In Saudi Arabia, Antibiotic resistant *Staphylococcus* spp. was detected in environmental and clinical settings [15-17]. A high prevalence of multidrug-resistant (MDR) *S. aureus* and *S. haemolyticus* was reported in Saudi Arabia, highlighting the significance of MDR *Staphylococcus* spp. in human infections [16, 17].

This study analyzed high and low-quality cosmetic products for *Staphylococcus* spp. prevalence and diversity. Biofilm forming capability and antimicrobial susceptibility profiles of detected *Staphylococcus* spp. were investigated as well. The study also explored antibiotic-resistant *Staphylococcus* spp. contamination in cosmetics, highlighting the associated health risks.

2. MATERIALS AND METHODS

2.1. Sampling

Factory-sealed and new samples (250) of different cosmetics were either purchased from malls and high street shops (branded high-quality products) or traditional markets (unbranded low-quality/counterfeit products) in Makkah, Saudi Arabia, from July to December 2022 (Table 1). The examination involved the assessment of external appearance, production and expiry dates, and manufacturing country.

Table 1. The cosmetic products examined in this study.

Total Number of Samples	Branded	Non Branded	Code	Contaminated Products	No.
51	3	48	LP	Lipstick	1
22	3	19	PW	Face powder	2
10	3	7	BL	Blusher	3
4	3	1	SG	Shower gel	4
29	3	26	M	Mascara	5
16	3	13	EY	Eyeliner	6
13	3	10	C	Concealer	7
15	0	15	F	Foundation	8
18	0	18	Gl	Glitter	9
6	0	6	Lg	Lip gloss	10
8	0	8	LN	Lenses	11
3	0	3	Pr	Primer	12
4	0	4	Hi	Highlighter	13

(Table 1) contd.....

Total Number of Samples	Branded	Non Branded	Code	Contaminated Products	No.
4	3	1	Tp	Toothpaste	14
11	0	11	Fc	Face cream	15
7	0	7	Sc	Scrub cream	16
7	0	7	Mw	Mouth wash	17
7	0	7	Sh	Shampoo	18
6	0	6	Cw	Cleansing water	19
2	0	2	Cr	Body lotion	20
4	3	1	MR	Makeup remover	21
3	3	0	Es	Eye shadow	22
250	30	220		All products	

Table 2. PCR primers of biofilm formation and methicillin-resistance-encoding genes.

Gene	Primer Sequence	Annealing Temperature	Amplicon Size (bp)
<i>icaR</i> -F	5' - TAA TCC CGA ATT TTT GTG AA-3'	52.0 °C	469
<i>icaR</i> -R	5' - AAC GCA ATA ACC TTA TTT TCC-3'		
<i>icaA</i> -F	5' - ACA GTC GCT ACG AAA AGA AA- 3'	53.2 °C	103
<i>icaA</i> -R	5 - GGA AAT GCC ATA ATG ACA AC- 3'		
<i>icaD</i> -F	5 - ATG GTC AAG CCC AGA CAG AG- 3'	53.5 °C	198
<i>icaD</i> -R	5' CGT GTT TTC AAC ATT TAA TGC AA-3'		
<i>icaB</i> -F	5' - CTG ATC AAG AAT TTA AAT CAC AAA- 3'	53.2 °C	302
<i>icaB</i> -R	5' - AAA GTC CCA TAA GCC TGT TT-3'		
<i>icaC</i> -F	5' - TAA CTT TAG GCG CAT ATG TTT T-3'	52.8 °C	400
<i>icaC</i> - R	5' - TTC CAG TTA GGC TGG TAT TG-3'		
<i>mecA</i> - F	5' - AAAATCGATGGTAAAGGTTGGC- 3'	55.0 °C	533
<i>mecA</i> - R	5' - AGTTCGTCAGTACCGGATTTCG- 3'		

2.2. Detection and Identification of *Staphylococcus* spp.

The enrichment and selective plating were performed to detect *Staphylococcus* spp. in cosmetics. Briefly, powdered and solid products (1 g) were aseptically added to peptone water (9 mL) (Oxoid, UK) in screw-top universal bottles. The enrichment was carried out by aerobically incubating (37 °C) for 24-48 h. After incubation, the enrichment bottles with turbidity were considered positive for microbial contamination. Each enrichment sample was individually streaked on mannitol salt agar (MSA) (Oxoid) plates and aerobically incubated (37 °C) for 24-48 h [15]. MSA plates presenting yellow colonies with yellow surrounding zones (*S. aureus* colonies) and colorless or pink colonies with red surrounding zones (staphylococci colonies other than *S. aureus*) were considered presumptive positive results. The sheep blood (5%) supplemented Columbia blood agar (Oxoid) was used to purify presumptive *Staphylococcus* spp. colonies. Three colonies were selected from each plate for the purification process [16, 17]. *Staphylococcus* spp. presumptive colonies were further confirmed through a clumping factor test (MastStaph kit, Mast Diagnostics, UK), Gram staining, catalase test, hemolytic activity on sheep blood agar (Oxoid), and deoxyribonuclease production on DNase agar (Oxoid) [15-17]. The Vitek® 2 compact system (BioMérieux Inc., France) with GP and AST-N026 cards was used for further confirmation of *Staphylococcus* species and CoNS genera differentiation. The cards were inoculated according to the manufacturer's guidelines and incubated in

the system. The Advanced Expert System (AES, version 8.0) was employed to analyze the outputs [16, 17].

2.3. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility patterns of confirmed *Staphylococcus* spp. were evaluated using the Vitek® 2 compact system (BioMérieux Inc.). The estimation of susceptibility patterns of 16 antibiotics from 13 antimicrobial classes was based on their minimum inhibitory concentrations (MIC). The antibiotics included penicillins (oxacillin and benzylpenicillin), lincosamides (clindamycin), macrolides (erythromycin), tetracyclines (tetracyclines), ansamycins (rifampicin), folate pathway antagonists (trimethoprim/sulfamethoxazole), nitrofurans (nitrofurantoin), fluoroquinolones (moxifloxacin, ciprofloxacin, and levofloxacin), aminoglycosides (gentamicin), glycopeptides (vancomycin), streptogramin (quinupristin), glycyclines (tigecycline), and oxazolidinones (linezolid) [16, 17].

Clinical and Laboratory Standards Institute [18] guidelines were followed to interpret *Staphylococcus* spp. antimicrobial susceptibility patterns. The Vitek 2 compact system was used for cefoxitin and inducible clindamycin resistance screening tests.

2.4. Detection of Biofilm Formation and Methicillin-resistance-encoding Genes

A standard PCR protocol was adopted to detect biofilm formation-encoding genes (*icaR*, *icaA*, *icaD*, *icaB*, *icaC*). Briefly, an overnight incubated bacterial culture on brain-

heart infusion agar plates (Oxoid) was used for genomic DNA extraction. Bacterial colonies (1-2) were resuspended in sterile distilled water (20 mL) and incubated (100 °C) for 20 minutes. A 5 µL aliquot of this suspension was used as the template DNA for PCR amplification in a thermal cycler (UNO II Thermocycler, Germany). Table 2 depicts the primer sequences (forward and reverse), and amplicon sizes of *icaR*, *icaD*, *icaB*, *icaC*, and *icaA* genes. The reaction mixture (25 µL) consisted of reverse and forward primers (2.5 µL of 1 M each), DNA template (5 µL of 150 ng), EzWay TMPCR Master Mix (10 µL) (LabisKoma, Korea), Taq DNA polymerase (1 U), and distilled water (5 µL). The amplification protocol included initial denaturation (94°C for 5 minutes) followed by 50 cycles of denaturation, annealing, and extension [(94°C for 30 s), (55.5°C for 30 s), (72°C for 30 s)], and a final extension (72°C for 1 minute). Furthermore, ethidium bromide-stained agarose gel electrophoresis (2% agarose in Tris-borate-EDTA) was performed using amplified PCR products (10 µL). The Gene Ruler DNA ladder (Koma Biotech Inc., Korea) of 100 bp served as the DNA marker [19]. The methicillin resistance (*mecA*) gene was also detected through the standard PCR method. Table 2 presents the primer sequences and relevant amplicon sizes. Biofilm formation-encoding genes were detected according to the same PCR protocol as mentioned above [20].

2.5. Control Strains

Staphylococcus epidermidis ATCC® 12228™ and

Staphylococcus aureus ATCC® BAA-1026™ were used as the control strains.

2.6. Statistical Analysis

One-way ANOVA was performed to differentiate the samples whereas the means were compared by Tukey's post hoc test. The results are presented as mean ± standard error. A Paired T-test was performed for the group comparison at $P < 0.05$.

3. RESULTS

3.1. Prevalence and Diversity of *Staphylococcus* spp. in Cosmetic Products

The results demonstrated 26 (10.4%) *Staphylococcus* spp. positive samples out of 250 samples of cosmetic products (Table 3). Product type-based further classification revealed the highest contamination (50%) in Blusher samples followed by 25%, 18.9%, 17.6%, 13.8%, 12.5%, and 7.7% in shower gel, face powder, lipstick, mascara, eyeliner, and concealer, respectively (Table 3). *S. xylosus* had the highest prevalence of 23.08% among *Staphylococcus* spp. isolates followed by 19.23%, 15.38%, 11.54%, and 11.54% of *S. epidermidis*, *S. warneri*, *S. hominis*, and *S. sciuri*, respectively. *S. lentus* and *S. aureus* had a similar prevalence of 7.69%, whereas the lowest prevalence of *S. haemolyticus* was noted as 3.84% (Table 4).

Table 3. Prevalence of *Staphylococcus* spp. in cosmetic products.

Source of Isolates	No. of Examined Samples	Positive Samples		Negative Samples	
		No.	%	No.	%
Lipstick (LP)	51	9	17.6	42	82.35
Blusher (BL)	10	5	50	5	50
Face powder (PW)	22	4	18.18	18	81.81
Mascara(M)	29	4	13.79	25	86.20
Eyeliner (EY)	16	2	12.5	14	87.5
Concealer(C)	13	1	7.69	12	92.30
Shower gel (SG)	4	1	25	3	75
Glitter (GL)	18	0	0	18	100
Lip gloss (LG)	6	0	0	6	100
Lenses (LN)	8	0	0	8	100
Foundation (F)	15	0	0	15	100
Primer (Pr)	3	0	0	3	100
Highlighter (Hi)	4	0	0	4	100
Toothpaste (Tp)	4	0	0	4	100
Face cream (Fc)	11	0	0	11	100
Scrub cream (Sc)	7	0	0	7	100
Mouthwash (Mw)	7	0	0	7	100
Shampoo (Sh)	7	0	0	7	100
Cleansing water (Cw)	6	0	0	6	100
Body lotion (Cr)	2	0	0	2	100
Makeup remover (MR)	4	0	0	4	100
Eye shadow (es)	3	0	0	3	100
All products	250	26	10.4	224	89.6
$P^{(a)}$	<0.001	$P^{(b)}$	<0.001	-	-

Note: (a) Overall prevalence of *Staphylococcus* spp. in branded and non-branded samples. (b) The percentage of *Staphylococcus* spp. in positive and negative samples.

Table 4. Diversity of *Staphylococcus* spp. in cosmetic products.

Species	Number of Isolates	%
<i>S. aureus</i>	2	7.69
<i>S. epidermidis</i>	5	19.23
<i>S. lentus</i>	2	7.69
<i>S. hominis ssp. hominis</i>	3	11.54
<i>S. sciuri</i>	3	11.54
<i>S. warneri</i>	4	15.38
<i>S. xylosus</i>	6	23.08
<i>S. haemolyticus</i>	1	3.84
-	$P^{(a)}$	<0.001
-	$P^{(b)}$	<0.001

(a) Overall prevalence of *Staphylococcus* spp. in branded and non-branded samples. (b) The percentage of *Staphylococcus* spp. in positive samples.

3.2. Antimicrobial Susceptibility Patterns of *Staphylococcus* spp. in Cosmetic Products

The data of antimicrobial susceptibility patterns of *Staphylococcus* spp. illustrated that 61.53% of *Staphylococcus* spp. isolates were resistant to benzylpenicillin (Penicillins), whereas resistance to tetracycline (Tetracyclines) was noted in 30.76% of isolates. The resistance to oxacillin (Penicillins) and erythromycin (Macrolides) was noted in 26.92% of isolates, whereas 19.23% of isolates were resistant to clindamycin (Lincosamides) (Table 5). A comparatively lower resistance of 7.69% and 3.84% was noted in trimethoprim/sulfamethoxazole (folate pathway antagonists), and rifampicin, respectively (Table 5). None of the *Staphylococcus* spp. isolates were resistant to all tested antibiotics (fluoroquinolones, streptogramin, glycyclines, aminoglycosides, oxazolidinones, nitrofurans, and glycopeptides) (Table 5). Five *Staphylococcus* spp. isolates, including four *S. xylosus* and one *S. lentus* isolate, exhibited multidrug resistance (MDR) (Table 6). *S.*

epidermidis and *S. aureus* isolates did not exhibit MDR patterns (Table 6). Multidrug resistance patterns included resistance to rifampicin, benzylpenicillin, trimethoprim/sulfamethoxazole, oxacillin, clindamycin, erythromycin, and tetracycline (Table 6).

3.3. Molecular Detection of Biofilm Formation and Methicillin Resistance-encoding Genes

PCR analysis detected the biofilm formation-linked genes in eight selected *Staphylococcus* spp. isolates in cosmetic samples. All the tested *Staphylococcus* spp. isolates possessed *icaR*, *icaD*, *icaC*, *icaB*, and *icaA* encoding genes (Table 7 and Fig. 1A-E). The *icaA* and *icaB* genes were detected in 50% (four isolates), whereas the prevalence of the *icaC*, *icaD*, and *icaR* genes was 37.5% (three out of eight isolates) (Table 7). Three isolates of *S. haemolyticus*, *S. aureus*, and *S. epidermidis* tested positive for all the *ica* genes (Table 7). The methicillin resistance-encoding gene (*mecA*) was detected in only three of the eight tested isolates (Table 8, Fig. 2).

Table 5. Overall resistance profiles of *Staphylococcus* spp. in cosmetic products.

Antibiotics	Drug Class	No. of Resistant (%) <i>Staphylococcus</i> spp. (n= 26)
Benzylpenicillin Oxacillin	Penicillins	16 (61.53) 7 (26.92)
Erythromycin	Macrolides	7 (26.92)
Clindamycin	Lincosamides	5 (19.23)
Tetracycline	Tetracyclines	8 (30.76)
Trimethoprim/Sulfamethoxazole	Folate pathway antagonist	2 (7.69)
Rifampicin	Ansamycins	1 (3.84)
Ciprofloxacin Levofloxacin Moxifloxacin	Fluoroquinolones	0 (0) 0 (0) 0 (0)
Gentamicin	Aminoglycosides	0 (0)
Nitrofurantoin	Miscellaneous	0 (0)
Vancomycin	Glycopeptides	0 (0)
Tigecycline	Glycyclines	0 (0)
Linezolid	Oxazolidinones	0 (0)
Quinupristin	Streptogramin	0 (0)




Fig. (1A). Agarose gel electrophoresis showing positive results for the *icaR* biofilm gene at 469 bp in *Staphylococcus* spp. Lane (L): 1 kb DNA marker, Lane (NC): negative control, Lane (QC1): positive control (*S. aureus* ATCC BAA-1026), and Lane (QC2): positive control (*S. epidermidis* ATCC 12228). Positive samples include Pw10 (*S. haemolyticus*), SgA2 (*S. epidermidis*), LP27 (*S. epidermidis*), BLA (*S. epidermidis*), BLB (*S. epidermidis*), C7 (*S. aureus*), BLBc (*S. epidermidis*), and LP24 (*S. aureus*).




Fig. (1B). Agarose gel electrophoresis shows positive results of the *icaA* Biofilm gene at (103 bp) in *Staphylococcus* spp. Where Lane (L) 1 kb DNA marker, Lane (NC) negative control, Lanes (QC1): positive (*S. aureus* ATCC BAA-1026), and Lane (QC2): positive (*S. epidermidis* ATCC12228). Lanes Pw10 (*S. haemolyticus*); SgA2 (*S. epidermidis*); LP27 (*S. epidermidis*), BLA (*S. epidermidis*); BLB (*S. epidermidis*), C7 (*S. aureus*), BLBc (*S. epidermidis*), LP24 (*S. aureus*).




Fig. (1C). Agarose gel electrophoresis shows positive results of the *icaD* Biofilm gene at (198 bp) in *Staphylococcus* spp. Where Lane (L) 1 kb DNA marker, Lane (NC) negative control, and Lanes (QC1): positive (*S. aureus* ATCC BAA-1026), and Lane (QC2): positive (*S. epidermidis* ATCC12228). Lanes Pw10 (*S. haemolyticus*); SgA2 (*S. epidermidis*); LP27 (*S. epidermidis*), BLA (*S. epidermidis*); BLB (*S. epidermidis*), C7 (*S. aureus*), BLBc (*S. epidermidis*), LP24 (*S. aureus*).




Fig. (1D). Agarose gel electrophoresis shows positive results of *icaB* Biofilm gene at (302 bp) in *Staphylococcus* spp. Where Lane (L) 1 kb DNA marker, Lane (NC) negative control, Lanes (QC1): positive (*S. aureus* ATCC BAA-1026), and Lane (QC2): positive (*S. epidermidis* ATCC12228). Lanes Pw10 (*S. haemolyticus*); SgA2 (*S. epidermidis*); LP27 (*S. epidermidis*), BLA (*S. epidermidis*); BLB (*S. epidermidis*), C7 (*S. aureus*), BLBc (*S. epidermidis*), LP24 (*S. aureus*).




Fig. (1E). Agarose gel electrophoresis shows positive results of the *icaC* Biofilm gene at (400 bp) in *Staphylococcus* spp. Where Lane (L) 1 kb DNA marker, Lane (NC) negative control, and Lanes (QC1): positive (*S. aureus* ATCC BAA-1026), and Lane (QC2): positive (*S. epidermidis* ATCC12228). Lanes Pw10 (*S. haemolyticus*); SgA2 (*S. epidermidis*); LP27 (*S. epidermidis*), BLA (*S. epidermidis*); BLB (*S. epidermidis*), C7 (*S. aureus*), BLBc (*S. epidermidis*), LP24 (*S. aureus*).

Table 6. Antimicrobial resistance patterns of *Staphylococcus* spp. in cosmetic products.

Isolate Code	Species	Origin	Resistance Type	No. of Classes	Resistance Type	Cefoxitin Screening*	Inducible Clindamycin Resistance*
LP3	<i>S. lentus</i>	Lipstick	BEN/ OX	1	-	-	-
LP24(1)	<i>S. aureus</i>	Lipstick	BEN/ OX/ TET	2	-	+	-
LP27	<i>S. epidermidis</i>	Lipstick	BEN/ E	2	-	-	-
LP33A	<i>S. hominis</i> ssp. <i>hominis</i>	Lipstick	BEN/ OX/ TET	2	-	+	-
LP33B	<i>S. sciuri</i>	Lipstick	0	0	-	-	-
LP38A	<i>S. xylosus</i>	Lipstick	E/ CL/ TET/ TRIM	4	MDR	-	-
LP38B	<i>S. xylosus</i>	Lipstick	BEN/ OX/E/ TET/ TRIM	4	MDR	+	-
LP39A	<i>S. xylosus</i>	Lipstick	E/ CL/ TET	3	MDR	-	-
LP39B	<i>S. xylosus</i>	Lipstick	E/ CL/ TET	3	MDR	-	-
BL3	<i>S. sciuri</i>	Blusher	0		-	-	-
BL5	<i>S. sciuri</i>	Blusher	BEN	1	-	-	-
BLA	<i>S. epidermidis</i>	Blusher	BEN	1	-	-	-

(Table 6) contd....

Isolate Code	Species	Origin	Resistance Type	No. of Classes	Resistance Type	Cefoxitin Screening*	Inducible Clindamycin Resistance*
BLB	<i>S. epidermidis</i>	Blusher	BEN	1	-	-	-
BLBc	<i>S. epidermidis</i>	Blusher	BEN	1	-	-	-
PW1	<i>S. xylosus</i>	Face powder	0	0	-	-	-
PW2	<i>S. warneri</i>	Face powder	BEN	1	-	-	-
PW10	<i>S. haemolyticus</i>	Face powder	BEN/ OX	1	-	+	-
PW14(2)	<i>S. lentus</i>	Face powder	BEN/OX/CL/ RIF	3	MDR	+	-
M2A	<i>S. warneri</i>	Mascara	BEN/E	2	-	-	-
M2A1	<i>S. hominis ssp. hominis</i>	Mascara	BEN/E	2	-	-	-
M2BA	<i>S. warneri</i>	Mascara	0		-	-	-
M2BB	<i>S. hominis ssp. hominis</i>	Mascara	0		-	-	-
EY5	<i>S. xylosus</i>	Eyeline	0		-	-	-
EY6	<i>S. warneri</i>	Eyeline	0		-	-	-
C7	<i>S. aureus</i>	Concealer	BEN/ OX/ TET	2	-	+	-
SgA2	<i>S. epidermidis</i>	Shower gel	BEN/ TET	2	-	-	-

BEN=Benzylpenicillin, OX=Oxacillin, Ery=Erythromycin, TET=Tetracycline, CLIN=Clindamycin, RIF=Rifampicin, Gen=Gentamicin, CIP= Ciprofloxacin, Levo=Levofloxacin, Mox=Moxifloxacin, Qui=Quinupristin, Lin=Linezolid, Van=Vancomycin, Tig=Tigecycline, Nit= Nitrofurantoin, Tri=Trimethoprim/Sulfamethoxazole.

MDR = Multidrug-resistance

Note: *Cefoxitin screening and inducible clindamycin resistance were determined by the Vitek 2 compact system

Table 7. Prevalence of biofilm formation-encoding genes in *Staphylococcus* spp. of different cosmetic products.

Isolate Origin	Species	Biofilm Formation-encoding Genes				
		<i>icaA</i>	<i>icaB</i>	<i>icaC</i>	<i>icaD</i>	<i>icaR</i>
PW10 /face powder	<i>S. haemolyticus</i>	+	+	+	+	+
SgA2/shower gel	<i>S. epidermidis</i>	-	-	-	-	-
LP27/lipstick	<i>S. epidermidis</i>	+	+	+	+	+
BLA/blusher	<i>S. epidermidis</i>	+	+	+	-	-
BLB/blusher	<i>S. epidermidis</i>	-	-	-	-	-
C7/concealer	<i>S. aureus</i>	-	-	-	-	-
BLBc/blusher	<i>S. epidermidis</i>	-	-	-	-	-
LP24/lipstick	<i>S. aureus</i>	+	+	-	+	+
Total	8	4 (50)	4 (50)	3 (37.5)	3 (37.5)	3 (37.5)

Table 8. Prevalence of *mecA* gene in *Staphylococcus* spp. of different cosmetic products.

Isolate Origin	Species	Methicillin-resistance Gene
		<i>mecA</i>
PW10/face powder	<i>S. haemolyticus</i>	+
SgA2/shower gel	<i>S. epidermidis</i>	-
LP27/lipstick	<i>S. epidermidis</i>	-
BLA/blusher	<i>S. epidermidis</i>	-
BLB/blusher	<i>S. epidermidis</i>	-
C7/concealer	<i>S. aureus</i>	+
BLBc/blusher	<i>S. epidermidis</i>	-
LP24/lipstick	<i>S. aureus</i>	+
Total	8	3 (37.5)




Fig. (2). Agarose gel electrophoresis shows positive results of the *mecA* Biofilm gene at (533 bp) in *Staphylococcus* spp. Where Lane (L) 1 kb DNA marker, Lane (NC) negative control, and Lanes (QC1): positive (*S. aureus* ATCC BAA-1026), and Lane (QC2): positive (*S. epidermidis* ATCC12228). Lanes Pw10 (*S. haemolyticus*); SgA2 (*S. epidermidis*); LP27 (*S. epidermidis*), BLA (*S. epidermidis*); BLB (*S. epidermidis*), C7 (*S. aureus*), BLBc (*S. epidermidis*), LP24 (*S. aureus*).

4. DISCUSSION

The usage of cosmetic products has become a necessary daily routine in recent times [2]. Consumers are turning towards biologically derived beauty products, which has facilitated significant growth of the global cosmetics market [21]. Cosmetic production often utilizes non-sterile raw materials, however, they are considered safe if bacterial counts remain within the permissible limit. For example, the bacterial count in eye-related cosmetics should remain below 500 CFU/g, whereas 1000 CFU/g is the maximum limit for other cosmetics of 1 g or 1 mL size [22]. The sterilization of cosmetic products is not carried out even though they might contain infectious bacteria. However, cosmetic products should be free from pathogens such as *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Escherichia coli*. Moreover, maintaining a lower microbial count is mandatory [4].

Staphylococcus spp. are a common part of skin microbiota that justifies their frequent detection in cosmetics. However, certain *Staphylococcus* spp. isolates can be pathogenic and cause skin infections [23]. This study thoroughly examined the diversity, antimicrobial susceptibility patterns, and biofilm formation of *Staphylococcus* spp. in cosmetic products of various qualities in Western Saudi Arabia. The results revealed *Staphylococcus* spp. contaminations in cosmetic products. A total of 250 samples were analyzed, and 26 samples emerged positive for *Staphylococcus* spp. Most *Staphylococcus* spp. were detected in the eyes and lips-related cosmetic products. These results are in line with the findings of Nasir and Qasim [24], who also observed the highest *Staphylococcus epidermidis* concentrations in eyeliners and lipsticks in Iraq. Alshehrei [25] also reported that *S. epidermidis* and *S. aureus* were prominent Gram-positive species in eyeliner, lipstick, and lip-gloss products of Makkah, Saudi Arabia.

This study further confirms previous findings by detecting significant bacterial levels of different

Staphylococcus species in lipstick and eyeliner, including the pathogenic *S. epidermidis* and *S. aureus*. The favorable conditions in moist cosmetic products may contribute to the higher levels of *Staphylococcus* spp. The prevalence of pathogenic *Staphylococcus* spp. in eyeliners could result in eyelid inflammation and blepharitis [26].

A higher prevalence of *Staphylococcus* spp. was noted in non-branded cosmetics (low-quality/counterfeit products). In addition to lipstick and eyeliners, other low-quality products (mascara, blushers, face powders, shower gels, and concealers) from traditional local markets have also tested positive for different pathogenic *Staphylococcus* spp. (*S. haemolyticus*, *S. aureus*, and *S. epidermidis*) [27]. Less pathogenic species (*S. hominis* and *S. warneri*) were also detected in low-quality cosmetics. However, recent studies have reported opportunistic infections of these less pathogenic species in immunocompromised individuals [28]. Fatima [29] also reported the presence of *S. haemolyticus* and *S. hominis* in cosmetic products. The prevalence of potentially pathogenic *Staphylococcus* spp. in low-quality or counterfeit cosmetics indicates poor manufacturing, handling, storage, and transportation conditions. Nusrat *et al.* [23] investigated microbial contamination in local cosmetics of Bangladesh and detected pathogenic bacteria (*Klebsiella pneumoniae*, *Staphylococcus* spp., *Pseudomonas aeruginosa*, *Streptococcus* spp., and *Salmonella* spp.) in more than 80% of tested products. They attributed these contaminations to poor manufacturing practices, storage and handling, and low-quality ingredients. Low-quality cosmetics might also contain hazardous ingredients, which could damage the skin and disrupt the normal skin microbial flora, leading to bacterial infections [30]. Thus, low-quality cosmetic products from unknown manufacturers should not be utilized to avoid potential pathogenic bacterial contaminations.

Antimicrobial susceptibility profiles of detected *Staphylococcus* spp. revealed a low prevalence of MDR strains in cosmetic products. *S. xylosus* was the only MDR species, which is not associated with human infections. Nonetheless, potentially pathogenic *S. haemolyticus*, *S. aureus*, and *S. epidermidis* isolates were resistant to tetracycline, benzylpenicillin, erythromycin, and oxacillin, which is in line with previous studies [31, 32]. Tetracycline and erythromycin are often administered against mild skin infections of *S. aureus*. However, the emergence of MRSA strains and tetracycline and erythromycin-resistant *S. aureus* strains have complicated their treatment [17]. Tetracycline and erythromycin resistance have also been reported in *S. haemolyticus* and *S. epidermidis* in nosocomial infections [16, 33]. The results revealed antibiotic resistance among less pathogenic *Staphylococcus* spp. including *S. xylosus*, *S. hominis*, *S. lentus*, *S. warneri*, and *S. sciuri*. These species demonstrated resistance against rifampicin, oxacillin, tetracycline, and clindamycin. Thus, these species might serve as reservoirs of resistance genes, which could spread to other clinical biofilm-forming staphylococci communities via horizontal gene transfer [34].

Biofilm-forming *Staphylococci* spp. are associated with chronic infections, particularly related to implanted medical devices [35]. *S. epidermidis* was reported as the first biofilm-producing species. Then, later studies reported biofilm formation in *S. aureus* and other CoNS (coagulase-negative staphylococci) as well [36]. Biofilms are exopolysaccharide matrix-surrounded bacterial aggregates on a surface [37]. The biofilm-forming capability enables inherent bacterial resistance to different antimicrobial drugs and the host's immune responses [38]. The results of this study depicted the presence of biofilm-encoding genes (*icaA* and *icaB*) in 50% of the examined (n = 8) *Staphylococcus* spp. (*S. haemolyticus*, *S. aureus*, and *S. epidermidis*). The same isolates also contained the *icaC* gene (*S. epidermidis*), *icaR* and *icaD* genes (*S. aureus*), and *icaR*, *icaD*, and *icaC* genes (*S. haemolyticus* and *S. epidermidis*). These isolates exhibited resistance to at least one antibiotic. It establishes a potential link between multidrug resistance and the biofilm formation capability of bacteria [21, 39-43].

This study highlights the public health concerns of *Staphylococcus* spp. contamination in cosmetic products in Western Saudi Arabia. The presence of MRSA and antibiotic-resistant biofilm-forming *S. haemolyticus* and *S. epidermidis* in cosmetic products suggest potential pathogenic transmission to consumers. Particularly, antibiotic-resistant bacteria (*S. haemolyticus*, *S. aureus*, and *S. epidermidis*) constitute serious health concerns as their treatments are complicated and thus might yield serious outcomes. The carriage of biofilm formation-encoding genes by *S. haemolyticus*, *S. aureus*, and *S.*

epidermidis further aggravates the situation. The biofilm-forming bacterial communities exert more resistance to antimicrobial agents, and these bacteria could acquire resistance-encoding genes via horizontal gene transfer. Therefore, the current study emphasizes strict regulation measures regarding the manufacturing, storage, and handling of cosmetics. The remedial measures could alleviate consumers' infection risks by preventing contaminated cosmetics-associated outbreaks.

5. STUDY LIMITATIONS

The current study comprehensively elaborates on various aspects of *Staphylococcus* spp. (prevalence, diversity, antimicrobial resistance, and biofilm formation in cosmetic products in Western Saudi Arabia. However, the following limitations should be considered as well.

- [1] **Sample size:** A total of 250 cosmetic samples were analyzed in this study, revealing *Staphylococcus* spp. contamination in 26 samples (10.4%) of the selected cosmetic products. However, analyzing a larger sample size of various cosmetic products across different geographic regions could provide a broader perspective and further validate the findings of this study.
- [2] **Geographic limitation:** The study primarily focused on Western Saudi Arabia, limiting the applicability of its findings to regions with different regulatory, manufacturing, and environmental conditions. Future studies should conduct national or multinational assessments to compare regional contamination rates in cosmetic products.
- [3] **Product classification:** The study compared branded (well-known brands) and non-branded (counterfeit and unknown) cosmetics, observing higher contamination rates in low-quality or counterfeit products. However, it lacks a systematic analysis of ingredient sources, as well as manufacturing and storage conditions. Future studies should further explore the role of these factors in microbial contamination.
- [4] **Longitudinal analysis:** This study only demonstrates *Staphylococcus* spp. contaminations in cosmetic products at a specific time. A future longitudinal study could reveal contamination variations over time in correlation with cosmetic products' shelf life, user habits, and storage conditions.
- [5] **Molecular and genomic characterization:** This study identified the *mecA* and biofilm formation-associated genes. However, the application of the whole-genome sequencing (WGS) technique in the future could facilitate detailed characterization of virulence factors, resistance genes, and potential horizontal gene transfer (HGT). Future investigations should also consider incorporating next-generation sequencing (NGS) for a detailed understanding of staphylococci resistance-related genetic mechanisms in cosmetic products.

6. RECOMMENDATIONS

The study highlights the significant public health risks associated with cosmetic contamination. The presence of

Staphylococcus spp., along with their antimicrobial susceptibility profiles and biofilm-forming capacity, further exacerbates the concern. The following recommendations may help mitigate these risks. Industrial scale regulatory measures:

Implementation of strict microbiological safety regulations during the manufacturing, storage, and distribution of cosmetic products is necessary to mitigate microbial contaminations. Regular microbial testing of cosmetic formulations should be mandatory to restrict bacterial count within judicial limits, particularly in lip and eye products. Potential contamination risks and recommended duration should be clearly labeled on the cosmetic products.

6.1. Surveillance and Antimicrobial Stewardship Program

Antibiotic resistance patterns of cosmetic-contaminating bacteria should be regularly monitored via an integrated surveillance system. It should particularly include the surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA). The collaboration of manufacturers, regulatory agencies, and healthcare authorities could help in the rapid evaluation of emerging antimicrobial resistance patterns in cosmetic products. Moreover, antimicrobial alternatives should be screened to restrict microbial contaminations in cosmetic products without exerting resistance selection pressure.

6.2. Consumer Awareness and Hygiene Practices

Consumer awareness is important regarding proper cosmetic handling and storage. Precautionary measures should include the usage of clean application tools, avoiding product sharing, and discarding expired products. Low-quality/counterfeit cosmetic products-related potential health risk awareness should be enhanced. The products manufactured without appropriate regulatory approval should be particularly focused. Additionally, innovative hygienic packaging such as antimicrobial applicators, airless pumps, and single-use cosmetic samples should be promoted to alleviate contamination risks.

7. FUTURE DIRECTIONS

The study emphasizes further investigations regarding bacterial prevalence, emergence of resistance, and contamination reduction strategies in cosmetic products.

7.1. Antimicrobial Resistance Mechanisms

Whole-genome sequencing and transcriptomic investigations could elucidate the mechanisms of antimicrobial resistance gene acquisition and transmission in cosmetics-associated *Staphylococcus* spp. Resistant bacterial isolates should be examined for biofilm formation-linked genes and efflux pump activity to enhance the understanding of bacterial resistance mechanisms in cosmetic formulations against antimicrobial agents.

7.2. Cosmetic Preservatives' Efficiency

Current cosmetic preservatives should be evaluated against multidrug-resistant (MDR) *Staphylococcus* spp. Novel antimicrobial agents (synthetic and natural), such as bio-based preservatives, essential oils, and nanoparticles, should be assessed as safer alternatives to traditional preservatives.

7.3. Risk Factors

Raw material sources, production conditions, and supply chain logistics should be assessed and monitored to avoid microbial contaminations. Moreover, metagenomics-based investigations of the entire microbial community in cosmetic products could provide insights into detailed microbial ecology.

7.4. Human Health Implications of Cosmetic-associated *Staphylococcus* spp.

Clinical studies are necessary to estimate infection risk from contaminated cosmetic products, particularly in immunocompromised individuals. The cosmetics should also be investigated in correlation with *Staphylococcus* spp. related skin conditions such as periocular infections, acne, conjunctivitis, and folliculitis

CONCLUSION

This study establishes cosmetic products as a significant medium for pathogenic microorganisms' transmission to humans. Particularly, the transmission of antibiotic-resistant *S. aureus* is seriously detrimental to human well-being. Moreover, the study correlates antibiotic resistance in staphylococci with their biofilm-forming capability. Collectively, the investigation emphasizes the implementation of health regulations at all stages of cosmetics production. Furthermore, it suggests the inclusion of preservatives without compromising human health while simultaneously hindering microbial growth during the manufacturing, preservation, transportation, and marketing of cosmetics. The insightful findings emphasize further large-scale investigations, genomic analyses, and clinical investigations for efficient microbial alleviation strategies. The collaboration of regulatory agencies, cosmetic producers, and healthcare professionals could ensure consumer safety by reducing antibiotic-resistant bacterial transmissions from everyday cosmetic products.

AUTHORS' CONTRIBUTIONS

H.H.A.: Conceptualization; H.H.A., F.M.A.b.: Methodology; M.S.A.H., H.H.A., S.A.G.: Investigation; M.S.A.H., H.H.A., L.A.N., F.M.A.b.: Data curation; F.M.A.B., R.A.A.G., L.A.N.: Formal analysis; H.H.A.: Resources; F.M.A.B.: Writing – original draft preparation; H.H.A., L.A.N.: Writing – review and editing; F.M.A.B.: Supervision; All authors have read and agreed to the published version of the manuscript.

LIST OF ABBREVIATIONS

MDR = Multidrug Resistant
 WGS = whole-genome sequencing
 NGS = Next-Generation Sequencing
 HGT = Horizontal Gene Transfer
 MRSA = Methicillin-Resistant *Staphylococcus aureus*

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIAL

All the data and supporting information are provided within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

- [1] Elmorsy TH, Hafez EA. Microbial contamination of some cosmetic preparations in egypt. *Agric Technol Thail* 2016; 12(3): 567-77.
- [2] Jairoun AA, Al-Hemyari SS, Shahwan M, Zyoud SH. An investigation into incidences of microbial contamination in cosmeceuticals in the UAE: Imbalances between preservation and microbial contamination. *Cosmetics* 2020; 7(4): 92. <http://dx.doi.org/10.3390/cosmetics7040092>
- [3] Skowron K, Jakubicz A, Budzyńska A, et al. Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date. *Rocz Panstw Zakl Hig* 2017; 68(2): 191-7. PMID: 28646837
- [4] Eldesoukey RMM, Alqhtani SB. Comparative microbiological study between traditional and modern cosmetics in saudi arabia. *Enzyme Eng* 2016; 5(2): 146. <http://dx.doi.org/10.4172/2329-6674.1000146>
- [5] Grice EA, Segre JA. The skin microbiome. *Nat Rev Microbiol* 2011; 9(4): 244-53. <http://dx.doi.org/10.1038/nrmicro2537> PMID: 21407241
- [6] Mueller NT, Bakacs E, Combellick J, Grigoryan Z, Dominguez-Bello MG. The infant microbiome development: Mom matters. *Trends Mol Med* 2015; 21(2): 109-17. <http://dx.doi.org/10.1016/j.molmed.2014.12.002> PMID: 25578246
- [7] Detmer A, Jørgensen C, Nylén D. A guidance document on microbiological control of cosmetic products. 2007. Available from: <https://www2.mst.dk/udgiv/publications/2010/978-87-92668-66-0/pdf/978-87-92668-67-7.pdf> [accessed on 28 September 2024].
- [8] Siegert W. Microbiological quality management for the production of cosmetics and detergents. 2012. Available from: https://www.researchgate.net/publication/233414828_Microbiological_Quality_Management_for_the_Production_of_Cosmetics_and_Detergents [accessed 05-July-2024].
- [9] Dadashi L, Dehghanzadeh R. Investigating incidence of bacterial and fungal contamination in shared cosmetic kits available in the women beauty salons. *Health Promot Perspect* 2016; 6(3): 159-63. <http://dx.doi.org/10.15171/hpp.2016.25> PMID: 27579260
- [10] Enemuor SC, Ojih MI, Isah S, Oguntibeju OO. Evaluation of bacterial and fungal contamination in hairdressing and beauty salons. *Afr J Microbiol Res* 2013; 7(14): 1222-5. <http://dx.doi.org/10.5897/AJMR12.917>
- [11] Samanta S, Singh BR, Adholeya A. Intracellular synthesis of gold nanoparticles using an ectomycorrhizal strain em-1083 of *laccaria fraterna* and its nanoanti-quorum sensing potential against *pseudomonas aeruginosa*. *Indian J Microbiol* 2017; 57(4): 448-60. <http://dx.doi.org/10.1007/s12088-017-0662-4> PMID: 29151646
- [12] Malak HA, Abulreesh HH, Organji SR, et al. Immune system evasion mechanisms in *Staphylococcus aureus*: Current understanding. *J Pure Appl Microbiol* 2020; 14(4): 2219-34. <http://dx.doi.org/10.22207/JPAM.14.4.01>
- [13] Kindi AA, Alkahtani AM, Nalubega M, et al. *Staphylococcus aureus* internalized by skin keratinocytes evade antibiotic killing. *Front Microbiol* 2019; 10: 2242. <http://dx.doi.org/10.3389/fmicb.2019.02242> PMID: 31608046
- [14] Duggal SD, Bharara T, Jena PP, et al. *Staphylococcal bullous impetigo* in a neonate. *World J Clin Cases* 2016; 4(7): 191-4. <http://dx.doi.org/10.12998/wjcc.v4.i7.191> PMID: 27458596
- [15] Organji SR, Abulreesh HH, Elbanna K, Osman GEH, Almalki MHK. Diversity and characterization of *Staphylococcus* spp. in food and dairy products: A foodstuff safety assessment. *J Microbiol Biotechnol Food Sci* 2018; 7: 586-93. <http://dx.doi.org/10.15414/jmbfs.2018.7.6.586-593>
- [16] Alahmadi TFH, Alahmadey ZZ, Organji SR, Elbanna K, Ahmad I, Abulreesh HH. First report of multi-drug resistant *Staphylococcus haemolyticus* in nosocomial infections in North Western Saudi Arabia. *J Pure Appl Microbiol* 2021; 15(2): 725-34. <http://dx.doi.org/10.22207/JPAM.15.2.24>
- [17] Alahmadi TFH, Alahmadey ZZ, Elbanna K, Neyaz LA, Ahmad I, Abulreesh HH. The prevalence and clinical characteristics of multidrug-resistant hospital-acquired *Staphylococcus aureus* in medina, saudi arabia. *J Pure Appl Microbiol* 2023; 17(1): 499-514. <http://dx.doi.org/10.22207/JPAM.17.1.44>
- [18] Performance standards for antimicrobial susceptibility testing. 2024. Available from: <https://clsi.org/standards/products/microbiology/documents/m100/> [accessed 1st July 2024].
- [19] El-Baky RMA, Gad GFM, El-Feky MA, El-Rehewy MS, Hassan MA, Abolella H. Detection of *icaA*, *icaD* genes and biofilm production by *Staphylococcus aureus* and *Staphylococcus epidermidis* isolated from urinary tract catheterized patients. *J Infect Dev Ctries* 2009; 3(5): 342-51. <http://dx.doi.org/10.3855/jidc.241> PMID: 19759503
- [20] Abulreesh HH, Organji SR, Osman GEH, Elbanna K, Almalki MHK, Ahmad I. Prevalence of antibiotic resistance and virulence factors encoding genes in clinical *Staphylococcus aureus* isolates in Saudi Arabia. *Clin Epidemiol Glob Health* 2017; 5(4): 196-202. <http://dx.doi.org/10.1016/j.cegh.2016.08.004>
- [21] Cerca N, Martins S, Cerca F, et al. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. *J Antimicrob Chemother* 2005; 56(2): 331-6. <http://dx.doi.org/10.1093/jac/dki217> PMID: 15980094
- [22] Ravita TD, Tanner RS, Ahearn DG, Arms EL, Crockett PW. Post-consumer use efficacies of preservatives in personal care and topical drug products: Relationship to preservative category. *J Ind Microbiol Biotechnol* 2009; 36(1): 35-8. <http://dx.doi.org/10.1007/s10295-008-0468-9> PMID: 18802729
- [23] Nusrat N, Zahra AM, Ahmed A, Haque F. Assessment of potential pathogenic bacterial load and multidrug resistance in locally

- manufactured cosmetics commonly used in Dhaka metropolis. Sci Rep 2023; 13(1): 7787.
<http://dx.doi.org/10.1038/s41598-023-34782-9> PMID: 37179424
- [24] Muntahaa NH. Microbiological contaminant isolation and detection in cosmetics sold in iraq. Inter J Pharma Res 2020; 12(4): 4434.
<http://dx.doi.org/10.31838/ijpr/2020.12.04.606>
- [25] Alshehrei FM. Isolation and identification of microorganisms associated with high-quality and low-quality cosmetics from different brands in mecca region -saudi arabia. Saudi J Biol Sci 2023; 30(12): 103852.
<http://dx.doi.org/10.1016/j.sjbs.2023.103852> PMID: 38020232
- [26] Campana R, Scesa C, Patrone V, Vittoria E, Baffone W. Microbiological study of cosmetic products during their use by consumers: Health risk and efficacy of preservative systems. Lett Appl Microbiol 2006; 43(3): 301-6.
<http://dx.doi.org/10.1111/j.1472-765X.2006.01952.x> PMID: 16910936
- [27] Abulreesh HH, Organji SR. The prevalence of multidrug-resistant staphylococci in food and the environment of Makkah, Saudi Arabia. Res J Microb 2011; 6(6): 510-23.
<http://dx.doi.org/10.3923/jm.2011.510.523>
- [28] Szemraj M, Grazul M, Balcerczak E, Szewczyk EM. Staphylococcal species less frequently isolated from human clinical specimens - are they a threat for hospital patients? BMC Infect Dis 2020; 20(1): 128.
<http://dx.doi.org/10.1186/s12879-020-4841-2> PMID: 32046678
- [29] Fathima N. Bacteriological evaluation and comparison of unused branded and non-branded cosmetic products available in jazan region of saudi arabia. J Microb World 2014; 16: 57-67.
- [30] Sonal A, Yadav A, Jain DK. Potential contamination in cosmetics: A review. Syst Rev Pharm 2023; 14: 641-9.
<http://dx.doi.org/10.31858/0975-8453.14.10.641-649>
- [31] Shaqra QMA, Al-Momani W, Al-Groom RM. Susceptibility of some bacterial contaminants recovered from commercial cosmetics in jordan to preservatives and antibiotics. Trop J Pharm Res 2014; 13(2): 255.
<http://dx.doi.org/10.4314/tjpr.v13i2.14>
- [32] Akgül Ö, Bakan K. Aerobic bacteria isolated from used cosmetic products and evaluation of antibiotic resistance. Ank Univ Facul Pharma J 2021; 45: 156-68.
<http://dx.doi.org/10.33483/jfpau.850561>
- [33] Chabi R, Momtaz H. Virulence factors and antibiotic resistance properties of the *Staphylococcus epidermidis* strains isolated from hospital infections in Ahvaz, Iran. Trop Med Health 2019; 47(1): 56.
<http://dx.doi.org/10.1186/s41182-019-0180-7> PMID: 31844416
- [34] Garbacz K, Wierzbowska M, Kwapisz E, et al. Distribution and antibiotic-resistance of different *Staphylococcus* species identified by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) isolated from the oral cavity. J Oral Microbiol 2021; 13(1): 1983322.
<http://dx.doi.org/10.1080/20002297.2021.1983322> PMID: 34594480
- [35] Osman KM, Abd El-Razik KA, Marie HSH, Arafa A. Relevance of biofilm formation and virulence of different species of coagulase-negative staphylococci to public health. Eur J Clin Microbiol Infect Dis 2015; 34(10): 2009-16.
<http://dx.doi.org/10.1007/s10096-015-2445-3> PMID: 26173695
- [36] Otto M. Staphylococcal biofilms. In: Romeo T, Ed. Bacterial Biofilms Current Topics in Microbiology and Immunology. Berlin, Heidelberg: Springer 2008.
http://dx.doi.org/10.1007/978-3-540-75418-3_10
- [37] Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15(2): 167-93.
<http://dx.doi.org/10.1128/CMR.15.2.167-193.2002> PMID: 11932229
- [38] Solati SM, Tajbakhsh E, Khamesipour F, Guhnani HC. Prevalence of virulence genes of biofilm producing strains of *Staphylococcus epidermidis* isolated from clinical samples in Iran. AMB Express 2015; 5(1): 47.
<http://dx.doi.org/10.1186/s13568-015-0134-3> PMID: 26253391
- [39] Cui J, Liang Z, Mo Z, Zhang J. The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China. Antimicrob Resist Infect Control 2019; 8(1): 65.
<http://dx.doi.org/10.1186/s13756-019-0523-5> PMID: 31044070
- [40] König C, Schwank S, Blaser J. Factors compromising antibiotic activity against biofilms of *Staphylococcus epidermidis*. Eur J Clin Microbiol Infect Dis 2001; 20(1): 20-6.
<http://dx.doi.org/10.1007/PL00011232> PMID: 11245318
- [41] Oliveira F, Cerca N. Antibiotic resistance and biofilm formation ability among coagulase-negative staphylococci in healthy individuals from Portugal. J Antibiot 2013; 66(12): 739-41.
<http://dx.doi.org/10.1038/ja.2013.90> PMID: 24045330
- [42] Seng R, Kittit T, Thummeepak R, et al. Biofilm formation of methicillin-resistant coagulase negative staphylococci (MR-CoNS) isolated from community and hospital environments. PLoS One 2017; 12(8): e0184172.
<http://dx.doi.org/10.1371/journal.pone.0184172> PMID: 28859149
- [43] Shrestha LB, Bhattarai NR, Khanal B. Antibiotic resistance and biofilm formation among coagulase-negative staphylococci isolated from clinical samples at a tertiary care hospital of eastern Nepal. Antimicrob Resist Infect Control 2017; 6(1): 89.
<http://dx.doi.org/10.1186/s13756-017-0251-7> PMID: 28883911